

## AEROSOL PHARMACEUTICAL PREPARATION

**Publication number:** RU2156135

**Publication date:** 2000-09-20

**Inventor:** GAPONJUK P JA; MARKOVA E A; MARKOV I A; GAPONJUK P P

**Applicant:** GAPONJUK PETR JAKOVLEVICH; MARKOVA ELENA ALEKSEEVNA; MARKOV IL JA ALEKSANDROVICH; GAPONJUK POLINA PETROVNA

**Classification:**

- **international:** A61K38/21; A61K38/21; (IPC1-7): A61K38/21

- **European:**

**Application number:** RU20000101760 20000127

**Priority number(s):** RU20000101760 20000127

**Report a data error here**

### Abstract of RU2156135

pharmaceutical industry. SUBSTANCE: interferon-base aerosol pharmaceutical preparation is prepared using liposomal suspension containing genetic engineering alpha-, beta- or gamma-interferon taken in the amount 1000-1000000 IU/1 ml of suspension. Preparation has additionally biologically compatible polymer, antioxidant, preserving agent or stabilizing agent and phosphatidylcholine and cholesterol also. Polyvinylpyrrolidone and/or polyethylene oxide is used as biologically compatible polymer. Trilon B is used as an antioxidant. Nipagin or bis-quaternary ammonium compounds, or chlorobutanol, or chlorohexane are used as preserving agent. Sucrose is used as stabilizing agent. Use of liposomal form ensures to attain therapeutic effects in acute viral infections of respiratory ways. Invention can be used for preparing medicinal aerosol preparations used both in medicine and for saturation of compartments used for animals and agriculture poultry care with drugs. EFFECT: rapid effect, absence of adverse effects and risk of infection using human interferon. 7 cl, 3 ex

Data supplied from the *esp@cenet* database - Worldwide